WJA
AERI

Williams Jones & Associates’s Aerie Pharmaceuticals AERI Stock Holding History

Williams Jones & Associates’s Portfolio AERI Stock Details AERI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-5,775
Closed -$274K – 424
2019
Q1 		$274K Hold
5,775
– – 0.01% 342
2018
Q4 		$208K Sell
5,775
-2,225
-28% -$104K 0.01% 354
2018
Q3 		$492K Buy
8,000
+3,050
+62% +$196K 0.01% 297
2018
Q2 		$334K Buy
+4,950
New +$277K 0.01% 338

Other funds holding AERI

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Williams Jones & Associates's AERI Position: Q2 2019 in Review

Williams Jones & Associates sold out of Aerie Pharmaceuticals (AERI) in Q2 2019, closing a stake of 5,775 shares — an estimated $274K sold.

Williams Jones & Associates first reported a position in AERI in Q2 2018 and held it in 4 quarters. The position peaked at $492K in Q3 2018. 167 funds tracked by Wall St. Rank hold AERI as of Q2 2019.

  • Williams Jones & Associates reported no remaining Aerie Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • Williams Jones & Associates sold 5,775 Aerie Pharmaceuticals shares in Q2 2019, an estimated $274K.
  • Williams Jones & Associates first reported a position in Aerie Pharmaceuticals in Q2 2018 and held it in 4 quarters.
  • Williams Jones & Associates's Aerie Pharmaceuticals position peaked at $492K in Q3 2018.
  • 167 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q2 2019.

Based on Williams Jones & Associates's 13F filing for Q2 2019, filed 14 Aug 2019.